The effects of treatment with interleukin‐1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis

Abstract

Treatment of RA with IL-1Ra resulted in reduced mononuclear cell infiltration of synovial membrane, which may represent the in vivo inhibition of biologically relevant IL-1ss-mediated pathogenic effects.

Synovial tissue research: a state-of-the-art review

“…43 A significant decrease of intimal lining CD68 macrophages was observed following rituximab infusion in responders. 54 Synovial response to rituximab has also been assessed by serial biopsy.…”

“…A significant decrease in ICAM-1 and VCAM-1 was seen in the high dose patients, and a small decrease in 2 of the 5 on the lower dose of anakinara. 43 …”

Interleukins in Atherosclerosis: Molecular Pathways and Therapeutic Potential

“…First discovered in the 1980s (Arend et al, 1985), this factor has been extensively studied as a potential anti-inflammatory compound. Systemic treatment with IL-1ra has been proven to be beneficial in the treatment of rheumatoid arthritis in animal models and in humans, as judged by histological and clinical improvement (Bresnihan et al, 1998;Cunnane et al, 2001). As discussed above, IL-1ra has also been suggested as an important protective factor in atherogenesis (Francis et al, 1999) and restenosis (Kastrati et al, 2000), and its administration is currently under scrutiny as a potential anti-atherogenic therapy.…”

Role of Interleukin 1 in the Development of Human Diseases

“…Ревматоидный артрит РА -первое заболевание, при котором была доказа-на эффективность анакинры [161][162][163][164][165][166][167][168][169], с применения ко-торой фактически и началась эра ГИБП в ревматологии. По данным экспериментальных исследований, у мышей с дефицитом ИЛ1Ра развивается тяжелый деструктивный артрит [170].…”